Xiaoyan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoyan Yu has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Qiang Zou
Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 shared publications - Jian-Hong Shi
Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University, Baoding, China (J.S., Yiyi Zhang, C.W.).
2 shared publications - Qiaoqiao Han
Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Ren Zhao
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Rui Ding
Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Xia Li
Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2) , e323986
NAT10-Mediated ac4C-Modification Exacerbates Ferroptosis by Stabilizing HMOX1 in Deep Vein Thrombosis
BACKGROUND: Deep vein thrombosis (DVT) is a prevalent peripheral vascular disorder associated with abnormal epigenetic processes and altered gene expression in endothelial cells. Accumulating evidence has demonstrated that NAT10 ( N -acetyltransferase 10)–mediated N 4-acetylcytidine modification exerts unique roles in ferroptosis, but its roles are still elusive in DVT. METHODS: To explore the potential mechanism of NAT10 and ferroptosis on thrombogenesis, we used NAT10 and GPX4 (glutathione peroxidase 4) knockout mice as an in vivo model, and utilized techniques, such as RNA immunoprecipitation, acRIP-qPCR (acetylated RNA immunoprecipitation-quantitative PCR), N 4-acetylcytidine Dot Blotting assay, and Western blotting, for detailed molecular analysis. RESULTS: GPX4 is a pivotal gene that suppresses ferroptosis. Utilizing endothelial cell–specific GPX4 conditional knockout mice (GPX4 fl/fl Cdh5-Cre + ), we proved that ferroptosis in endothelial cells promotes the formation of thrombosis. Previous evidence indicates that NAT10 overexpression induces ferroptosis and downregulates GPX4 expression. Here, we found that NAT10 expression was elevated in DVT mice, and silencing of NAT10 markedly attenuated ferroptosis both in vitro and in vivo. Furthermore, endothelial cell–specific knockout of NAT10 (NAT10 fl/fl Cdh5-Cre + ) demonstrated a reduction in endothelial ferroptosis, thereby inhibiting both the formation and progression of DVT. Mechanistic studies indicated that NAT10 facilitated the N4-acetylcytidine modification of HMOX1 (heme oxygenase 1), which enhanced its mRNA stability, leading to the accumulation of ferrous ions, and exacerbating endothelial dysfunction in DVT. CONCLUSIONS: Collectively, our data elucidate that downregulation of NAT10 mitigates endothelial ferroptosis and prevents DVT formation and progression by modulating HMOX1 expression, which offers a potential novel strategy for the prevention and treatment of thrombosis in DVT.
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2) , e323986
Top Cited PapersOpen AccessNAT10-Mediated ac4C-Modification Exacerbates Ferroptosis by Stabilizing HMOX1 in Deep Vein Thrombosis
BACKGROUND: Deep vein thrombosis (DVT) is a prevalent peripheral vascular disorder associated with abnormal epigenetic processes and altered gene expression in endothelial cells. Accumulating evidence has demonstrated that NAT10 ( N -acetyltransferase 10)–mediated N 4-acetylcytidine modification exerts unique roles in ferroptosis, but its roles are still elusive in DVT. METHODS: To explore the potential mechanism of NAT10 and ferroptosis on thrombogenesis, we used NAT10 and GPX4 (glutathione peroxidase 4) knockout mice as an in vivo model, and utilized techniques, such as RNA immunoprecipitation, acRIP-qPCR (acetylated RNA immunoprecipitation-quantitative PCR), N 4-acetylcytidine Dot Blotting assay, and Western blotting, for detailed molecular analysis. RESULTS: GPX4 is a pivotal gene that suppresses ferroptosis. Utilizing endothelial cell–specific GPX4 conditional knockout mice (GPX4 fl/fl Cdh5-Cre + ), we proved that ferroptosis in endothelial cells promotes the formation of thrombosis. Previous evidence indicates that NAT10 overexpression induces ferroptosis and downregulates GPX4 expression. Here, we found that NAT10 expression was elevated in DVT mice, and silencing of NAT10 markedly attenuated ferroptosis both in vitro and in vivo. Furthermore, endothelial cell–specific knockout of NAT10 (NAT10 fl/fl Cdh5-Cre + ) demonstrated a reduction in endothelial ferroptosis, thereby inhibiting both the formation and progression of DVT. Mechanistic studies indicated that NAT10 facilitated the N4-acetylcytidine modification of HMOX1 (heme oxygenase 1), which enhanced its mRNA stability, leading to the accumulation of ferrous ions, and exacerbating endothelial dysfunction in DVT. CONCLUSIONS: Collectively, our data elucidate that downregulation of NAT10 mitigates endothelial ferroptosis and prevents DVT formation and progression by modulating HMOX1 expression, which offers a potential novel strategy for the prevention and treatment of thrombosis in DVT.
- Open Access
- 1 December 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (12) , 113518
De novo NAD+ synthesis contributes to CD8+ T cell metabolic fitness and antitumor function
- 1 December 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (12) , 113518
Open AccessDe novo NAD+ synthesis contributes to CD8+ T cell metabolic fitness and antitumor function
- Open Access
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis
The functional integrity of Tregs is interwoven with cellular metabolism; however, the mechanisms governing Treg metabolic programs remain elusive. Here, we identified that the deubiquitinase USP47 inhibited c-Myc translation mediated by the RNA N6-methyladenosine (m6A) reader YTHDF1 to maintain Treg metabolic and functional homeostasis. USP47 positively correlated with the tumor-infiltrating Treg signature in samples from patients with colorectal cancer and gastric cancer. USP47 ablation compromised Treg homeostasis and function in vivo, resulting in the development of inflammatory disorders, and boosted antitumor immune responses. USP47 deficiency in Tregs triggered the accumulation of the c-Myc protein and in turn exacerbated hyperglycolysis. Mechanistically, USP47 prevented YTHDF1 ubiquitination to attenuate the association of YTHDF1 with translation initiation machinery, thereby decreasing m6A-based c-Myc translation efficiency. Our findings reveal that USP47 directs m6A-dependent metabolic programs to orchestrate Treg homeostasis and suggest novel approaches for selective immune modulation in cancer and autoimmune diseases by targeting of USP47.
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
Open AccessUSP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis
The functional integrity of Tregs is interwoven with cellular metabolism; however, the mechanisms governing Treg metabolic programs remain elusive. Here, we identified that the deubiquitinase USP47 inhibited c-Myc translation mediated by the RNA N6-methyladenosine (m6A) reader YTHDF1 to maintain Treg metabolic and functional homeostasis. USP47 positively correlated with the tumor-infiltrating Treg signature in samples from patients with colorectal cancer and gastric cancer. USP47 ablation compromised Treg homeostasis and function in vivo, resulting in the development of inflammatory disorders, and boosted antitumor immune responses. USP47 deficiency in Tregs triggered the accumulation of the c-Myc protein and in turn exacerbated hyperglycolysis. Mechanistically, USP47 prevented YTHDF1 ubiquitination to attenuate the association of YTHDF1 with translation initiation machinery, thereby decreasing m6A-based c-Myc translation efficiency. Our findings reveal that USP47 directs m6A-dependent metabolic programs to orchestrate Treg homeostasis and suggest novel approaches for selective immune modulation in cancer and autoimmune diseases by targeting of USP47.
- Open Access
- 6 September 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4013707
Edaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP‐1‐Mediated Inhibition of MAPKs and Activation of Nrf2
The edaravone and dexborneol concentrated solution for injection (edaravone‐dexborneol) is a medication used clinically to treat neurological impairment induced by ischemic stroke. This study was aimed at investigating the preventive effects and the underlying mechanisms of edaravone‐dexborneol on cerebral ischemic injury. A rat four‐vessel occlusion (4‐VO) model was established, and the neuronal injury and consequent neurological impairment of rats was investigated. Brain tissue malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO) levels were determined. The levels of proteins in mitogen‐activated protein kinases (MAPKs), nuclear factor erythroid 2‐related factor 2 (Nrf2), and nuclear factor‐κB (NF‐κB) signaling pathways were determined by western immunoblotting. The function of mitogen‐activated protein kinase phosphatase 1 (MKP‐1) was investigated using both western blot and immunofluorescence methods, and the effect of the MKP‐1 inhibitor, (2E)‐2‐benzylidene‐3‐(cyclohexylamino)‐3H‐inden‐1‐one (BCI), was investigated. The results indicated that edaravone‐dexborneol alleviated neurological deficiency symptoms and decreased apoptosis and neuron damage in the hippocampal CA1 area of the ischemic rats. Edaravone‐dexborneol increased the MKP‐1 level; decreased the phosphorylation of extracellular signal‐regulated kinase (ERK), c‐Jun N‐terminal kinase (JNK), and p38 mitogen‐activated protein kinase (p38 MAPK); inhibited NF‐κB p65 activation; and boosted Nrf2 activation, all of which were partially reversed by the MKP‐1 inhibitor, BCI. The above results indicated that the upregulation of MKP‐1 contributed to the protective effects of edaravone‐dexborneol against ischemic brain injury. Our findings support the hypothesis that edaravone‐dexborneol can alleviate cerebral ischemic injury via the upregulation of MKP‐1, which inhibits MAPKs and activates Nrf2.
- 6 September 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4013707
Open AccessEdaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP‐1‐Mediated Inhibition of MAPKs and Activation of Nrf2
The edaravone and dexborneol concentrated solution for injection (edaravone‐dexborneol) is a medication used clinically to treat neurological impairment induced by ischemic stroke. This study was aimed at investigating the preventive effects and the underlying mechanisms of edaravone‐dexborneol on cerebral ischemic injury. A rat four‐vessel occlusion (4‐VO) model was established, and the neuronal injury and consequent neurological impairment of rats was investigated. Brain tissue malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO) levels were determined. The levels of proteins in mitogen‐activated protein kinases (MAPKs), nuclear factor erythroid 2‐related factor 2 (Nrf2), and nuclear factor‐κB (NF‐κB) signaling pathways were determined by western immunoblotting. The function of mitogen‐activated protein kinase phosphatase 1 (MKP‐1) was investigated using both western blot and immunofluorescence methods, and the effect of the MKP‐1 inhibitor, (2E)‐2‐benzylidene‐3‐(cyclohexylamino)‐3H‐inden‐1‐one (BCI), was investigated. The results indicated that edaravone‐dexborneol alleviated neurological deficiency symptoms and decreased apoptosis and neuron damage in the hippocampal CA1 area of the ischemic rats. Edaravone‐dexborneol increased the MKP‐1 level; decreased the phosphorylation of extracellular signal‐regulated kinase (ERK), c‐Jun N‐terminal kinase (JNK), and p38 mitogen‐activated protein kinase (p38 MAPK); inhibited NF‐κB p65 activation; and boosted Nrf2 activation, all of which were partially reversed by the MKP‐1 inhibitor, BCI. The above results indicated that the upregulation of MKP‐1 contributed to the protective effects of edaravone‐dexborneol against ischemic brain injury. Our findings support the hypothesis that edaravone‐dexborneol can alleviate cerebral ischemic injury via the upregulation of MKP‐1, which inhibits MAPKs and activates Nrf2.
- Open Access
- 1 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (7)
SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells
The functional integrity of CD8+ T cells is tightly coupled to metabolic reprogramming, but how oxidative stress directs CD8+ T cell metabolic fitness in the tumor microenvironment (TME) remains elusive. Here, we report that SUMO-specific protease 7 (SENP7) senses oxidative stress to maintain the CD8+ T cell metabolic state and antitumor functions. SENP7-deficient CD8+ T cells exhibited decreased glycolysis and oxidative phosphorylation, resulting in attenuated proliferation in vitro and dampened antitumor functions in vivo. Mechanistically, CD8+ T cell–derived ROS triggered cytosolic SENP7–mediated PTEN deSUMOylation, thereby promoting PTEN degradation and preventing PTEN-dependent metabolic defects. Importantly, lowering T cell–intrinsic ROS restricted SENP7 cytosolic translocation and repressed CD8+ T cell metabolic and functional activity in human colorectal cancer samples. Our findings reveal that SENP7, as an oxidative stress sensor, sustains CD8+ T cell metabolic fitness and effector functions and unveil an oxidative stress–sensing machinery in tumor-infiltrating CD8+ T cells.
- 1 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (7)
Open AccessSENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells
The functional integrity of CD8+ T cells is tightly coupled to metabolic reprogramming, but how oxidative stress directs CD8+ T cell metabolic fitness in the tumor microenvironment (TME) remains elusive. Here, we report that SUMO-specific protease 7 (SENP7) senses oxidative stress to maintain the CD8+ T cell metabolic state and antitumor functions. SENP7-deficient CD8+ T cells exhibited decreased glycolysis and oxidative phosphorylation, resulting in attenuated proliferation in vitro and dampened antitumor functions in vivo. Mechanistically, CD8+ T cell–derived ROS triggered cytosolic SENP7–mediated PTEN deSUMOylation, thereby promoting PTEN degradation and preventing PTEN-dependent metabolic defects. Importantly, lowering T cell–intrinsic ROS restricted SENP7 cytosolic translocation and repressed CD8+ T cell metabolic and functional activity in human colorectal cancer samples. Our findings reveal that SENP7, as an oxidative stress sensor, sustains CD8+ T cell metabolic fitness and effector functions and unveil an oxidative stress–sensing machinery in tumor-infiltrating CD8+ T cells.
- 25 February 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (6) , 835-846
Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy
Objective: The purpose of this research is to formulate a biomimetic drug delivery system, which can selectively target glioblastoma (GBM) to deliver the antitumor agent, Gboxin, a novel Complex V inhibitor. Gboxin can specifically inhibit GBM cell growth but not normal cells. Methods: In the present study, we utilized red blood cell (RBC) membrane and U251 cell membrane to obtain a hybrid biomimetic membrane (RBC-U), and prepared RBC-U coated Gboxin-loaded mesoporous silica nanoparticles ((MSNs/Gboxin)@[RBC-U]) for GBM chemotherapy. The zeta potential, particle size, and morphology of (MSNs/Gboxin)@[RBC-U] were characterized. The cellular uptake, effect of cells growth inhibition, biocompatibility, and specific self-recognition of nanoparticles were evaluated. Results: The (MSNs/Gboxin)@[RBC-U] was successfully fabricated and possessed high stability in the circulation system. The drug loading of Gboxin was 13.9%. (MSNs/Gboxin)@ [RBC-U] could effectively retain drugs in the physiological environment and released Gboxin rapidly in the tumor cells. Compared to the MSNs/Gboxin, the (MSNs/Gboxin)@[RBC-U] exhibit highly specific self-recognition to the source cell line. Additionally, the (MSNs/Gboxin) @[RBC-U] showed excellent anti-proliferation efficiency (IC50 = 0.21 μg/mL) in the tumor cell model and few side effects in normal cels in vitro. Conclusion: The (MSNs/Gboxin)@[RBC-U] exhibited significant anti-cancer effects in vitro and the specific self-recognition to GBM cells. Hence, (MSNs/Gboxin)@[RBC-U] could be a promising delivery system for GBM targeted therapy.
- 25 February 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (6) , 835-846
Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy
Objective: The purpose of this research is to formulate a biomimetic drug delivery system, which can selectively target glioblastoma (GBM) to deliver the antitumor agent, Gboxin, a novel Complex V inhibitor. Gboxin can specifically inhibit GBM cell growth but not normal cells. Methods: In the present study, we utilized red blood cell (RBC) membrane and U251 cell membrane to obtain a hybrid biomimetic membrane (RBC-U), and prepared RBC-U coated Gboxin-loaded mesoporous silica nanoparticles ((MSNs/Gboxin)@[RBC-U]) for GBM chemotherapy. The zeta potential, particle size, and morphology of (MSNs/Gboxin)@[RBC-U] were characterized. The cellular uptake, effect of cells growth inhibition, biocompatibility, and specific self-recognition of nanoparticles were evaluated. Results: The (MSNs/Gboxin)@[RBC-U] was successfully fabricated and possessed high stability in the circulation system. The drug loading of Gboxin was 13.9%. (MSNs/Gboxin)@ [RBC-U] could effectively retain drugs in the physiological environment and released Gboxin rapidly in the tumor cells. Compared to the MSNs/Gboxin, the (MSNs/Gboxin)@[RBC-U] exhibit highly specific self-recognition to the source cell line. Additionally, the (MSNs/Gboxin) @[RBC-U] showed excellent anti-proliferation efficiency (IC50 = 0.21 μg/mL) in the tumor cell model and few side effects in normal cels in vitro. Conclusion: The (MSNs/Gboxin)@[RBC-U] exhibited significant anti-cancer effects in vitro and the specific self-recognition to GBM cells. Hence, (MSNs/Gboxin)@[RBC-U] could be a promising delivery system for GBM targeted therapy.
- Open Access
- 23 December 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (2)
ZFP91 is required for the maintenance of regulatory T cell homeostasis and function
Autophagy programs the metabolic and functional fitness of regulatory T (T reg) cells to establish immune tolerance, yet the mechanisms governing autophagy initiation in T reg cells remain unclear. Here, we show that the E3 ubiquitin ligase ZFP91 facilitates autophagy activation to sustain T reg cell metabolic programming and functional integrity. T reg cell–specific deletion of Zfp91 caused T reg cell dysfunction and exacerbated colonic inflammation and inflammation-driven colon carcinogenesis. TCR-triggered autophagy induction largely relied on T reg cell–derived ZFP91 to restrict hyperglycolysis, which is required for the maintenance of T reg cell homeostasis. Mechanistically, ZFP91 rapidly translocated from the nucleus to the cytoplasm in response to TCR stimulation and then mediated BECN1 ubiquitination to promote BECN1–PIK3C3 complex formation. Therefore, our results highlight a ZFP91-dependent mechanism promoting TCR-initiated autophagosome maturation to maintain T reg cell homeostasis and function.
- 23 December 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (2)
Open AccessZFP91 is required for the maintenance of regulatory T cell homeostasis and function
Autophagy programs the metabolic and functional fitness of regulatory T (T reg) cells to establish immune tolerance, yet the mechanisms governing autophagy initiation in T reg cells remain unclear. Here, we show that the E3 ubiquitin ligase ZFP91 facilitates autophagy activation to sustain T reg cell metabolic programming and functional integrity. T reg cell–specific deletion of Zfp91 caused T reg cell dysfunction and exacerbated colonic inflammation and inflammation-driven colon carcinogenesis. TCR-triggered autophagy induction largely relied on T reg cell–derived ZFP91 to restrict hyperglycolysis, which is required for the maintenance of T reg cell homeostasis. Mechanistically, ZFP91 rapidly translocated from the nucleus to the cytoplasm in response to TCR stimulation and then mediated BECN1 ubiquitination to promote BECN1–PIK3C3 complex formation. Therefore, our results highlight a ZFP91-dependent mechanism promoting TCR-initiated autophagosome maturation to maintain T reg cell homeostasis and function.